DOCSLIB.ORG

(10) Patent No.: US 8748402 B2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(10) Patent No.: US 8748402 B2 USOO8748402B2 (12) United States Patent (10) Patent No.: US 8,748,402 B2 Abelson et al. (45) Date of Patent: *Jun. 10, 2014 (54) OPHTHALMIC FORMULATIONS AND USES 6,117,907 A 9, 2000 Sher THEREOF 6.432,934 B1 8, 2002 Gilbard 6,465,506 B2 10/2002 Abelson et al. 6,482,799 B1 1 1/2002 Tusé et al. (75) Inventors: Mark Abelson, Andover, MA (US); 6,599,891 B2 7/2003 North et al. Kirk McMullin, Villa Park, CA (US); 6,624, 193 B1 9/2003 Naka et al. Angel Padilla, Aliso Viejo, CA (US) 6,646,001 B2 11/2003 Hellberg et al. 6,699,493 B2 3/2004 Wong (73) Assignee: Bausch & Lomb Pharma Holdings 2004/0072809 A1 4/2004 Demopulos et al. Corp.,s Rochester,s NY (US) 2.93. A 3: ShayarkarSO et al. 2007,0254.841 A1 11/2007 Ousler et al. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U.S.C. 154(b) by 59 days. This patent is Subject to a terminal dis WO WO O2/49614 6, 2002 claimer. OTHER PUBLICATIONS (21) Appl. No.: 13/369,452 Tsubotaetal (Progress in Retinal and Eye Research vol. 17. No.4, pp. 565 to 596, 1998).* 1-1. International Search Report and Written Opinion issued by the World (22) Filed: Feb. 9, 2012 Intellectual Property Office, dated Dec. 20, 2006. (65) Prior Publication Data station Ety, rt Patentability issued by the World Intellectual Property Office, dated Oct. 30, 2007. US 2012/O195972 A1 Aug. 2, 2012 WWW.Ou.edureSearchWNN Built electronbmZals 3. uters.html.A PEast from http:// O O The Roberts Lab Group, SB (Sodium Borate) Buffer, 20x, printed Related U.S. Application Data from http://mmadisplay.usc.edu/lab? protocols/perfsb-Sodium (63) Continuation-in-part of application No. 1 1/146,652, borate-buffer-20x on May 22, 2010. filed on Jun. 7, 2005, now Pat. No. 8,372,814. www.teknova.com, 10x Borate Saline Buffer, printed from http:// www.teknova.com/product-p/b0230.htm May 22, 2010. (60) Provisional application No. 60/675,179, filed on Apr. Tananuvatet al. Controlled Study of the Use of Autologous Serum in 26, 2005, provisional application No. 60/577.567, Dry Eye Patients, Cornea vol. 20, No. 8 (2001), pp. 802-806. filed on Jun. 7, 2004. Engel et al. “Effectiveness of Specific Antibiotic/Steroid Combina tions for Therapy of Experimental Pseudomonas aerugionos (51) Int. Cl. Keratitis' Current Eye Research, vol. 4. No. 3 (1995) pp. 229-234. AOIN 43/04 (2006.01) Van Haeringen, "Clinical Biochemistry of Tears' Survey of A6 IK3I/70 (2006.01) Ophthamology, vol. 26, No. 2 (1991), pp. 84-96. (52) st (2006.01) * cited by examiner CPC ........................................ A61K 9/48 (2013.01) Primary Examiner — Benjamin Packard USPC ............................................. 514/40: 514/178 (74) Attorney, Agent, or Firm — Thompson Hine LLP (58) Field of Classification Search CPC ........................................................ A61 K9/48 (57) ABSTRACT USPC .................................................... 514/40, 178 See application file for complete search history Provided by the present invention are compositions or formu lations Suitable for application to a patient’s eyes which ulti (56) References Cited lizes a topical ophthalmically-acceptable formulation com prising a therapeutically-effective amount of an U.S. PATENT DOCUMENTS ophthalmically-active antimicrobial agent, and an ophthalmi cally-active anti-inflammatory or steroidal agent in combina 4,134,403 A 1/1979 Johnson et al. tion with physiologic levels of serum electrolytes in an oph 4,315,024 A 2f1982 Abelson 4,981,871 A 1/1991 Abelson thalmic formulation for the treatment of changes in the 5,290,781 A 3/1994 Espino et al. normal eye condition. The invention also includes methods of 5,340,572 A 8, 1994 Patel et al. treating patients having an ophthalmic disease, injury or 5,403,598 A 4/1995 Becket al. disorder, utilizing the compositions or formulations. Also 5,407,669 A 4/1995 Lindstrom et al. provided are kits comprising the compositions or formula 5,475,034 A 12/1995 Yanni et al. 5,624,893 A 4, 1997 Yanni tions and a means of applying the compositions or formula 5,767,105 A 6/1998 Peyman tion to the patient’s eyes. 5,811,446 A 9, 1998 Thomas 5,929, 111 A 7, 1999 Conrow et al. 32 Claims, No Drawings US 8,748,402 B2 1. 2 OPHTHALMC FORMULATIONS AND USES 85 to about 150 mg/L, and bicarbonate in a concentration THEREOF from about 1281 to about 2013 mg/L. The antimicrobial agent, and anti-inflammatory or steroi CROSS-REFERENCES TO RELATED dal agent of the composition or formulation are used to treat APPLICATIONS or mitigate the injury, disease or disorder. One steroidal agent contemplated in the present invention is prednisolone This application is a continuation in part of co-pending whereas a contemplated antimicrobial is tobramycin. application Ser. No. 1 1/146,652, filed Jun. 7, 2005, which The invention also includes methods of treating patients claims priority from U.S. Provisional Patent Applications having an ophthalmic disease, injury or disorder, utilizing the 60/577.567 filed Jun. 7, 2004, and 60/675,179 filed Apr. 26, 10 compositions or formulations. Further, the compositions or 2005, each of which is expressly incorporated by reference formulations can be utilized to restore the normal condition of the eye when the normal condition has been disrupted or herein in its entirety. changed. Also provided are kits comprising the compositions BACKGROUND OF THE INVENTION or formulations and a means of applying the compositions or 15 formulation to the patient’s eyes. The present invention relates to ophthalmic formulations, kits and uses thereof, wherein the formulations utilize physi DESCRIPTION OF THE INVENTION ologic levels of serum electrolytes in conjunction with phar Without being bound by a particular theory, it appears that macologically effective doses of an antimicrobial agent, and the physiology of the injured or diseased eye more closely an anti-inflammatory or steroidal agent in a single formula resembles the physiology of serum due to the release of vessel tion for the treatment of ocular disorders, diseases or injuries. contents into the tear film and, as Such, the contents are Combinations or formulations containing an antimicrobial pathological to the condition of the eye. Therefore, the appli agent and an anti-inflammatory agent are available in the cation of an ophthalmic formulation that mimics the injured ophthalmic art. However, there are concerns and expressed 25 eye condition is a focus of the present invention, since the reservations in the ophthalmic community about the safety application of such a formulation does not shock the already and efficacy of Such prior art combinations. There continues overly-sensitized tissues and is able to gradually restore the to be a need for an effective and safe topical ophthalmic eye to a normal condition (i.e. non-inflamed and non-infected pharmaceutical composition of a steroid oranti-inflammatory state). Such an approach is counterintuitive to conventional agent and a broad spectrum antibiotic which, when adminis 30 therapies, since physicians presently would not use a formu tered to the eye will not inhibit the activity of the antibiotic, or lation that continues the pathologic condition within the eye. steroidal or anti-inflammatory components. Nevertheless, it is important to consider that the addition of a Many ophthalmic conditions result in an aberrant tear film formulation with electrolytes in “equilibrium' with the elec composition. The electrolyte balances and concentrations in trolytes in the “inflamed eye may provide several advantages tears can change as a result of a disruption in the normal eye 35 when used in conjunction with an antimicrobial and a steroi physiology. For example, when ocular tissue is inflamed, dal or anti-inflammatory agent. Such advantages could serum components leak from the vasculature into the tear include, but are not necessarily limited to, a formulation that film. Many of these ophthalmic conditions are typically is more comfortable to the patient which may result in better treated with antimicrobial and/or steroidal or anti-inflamma patient compliance and/or a formulation that promotes faster tory compounds. 40 healing. SUMMARY OF THE INVENTION Definitions The present invention comprises a formulation which “Ophthalmically-acceptable” means that the formulation, mimics the serum components of the injured eye (instead of 45 active agent, excipient or other material is compatible with the normal eye tear physiology) which when used in conjunc ocular tissue; that is, it does not cause significant or undue tion with an antimicrobial, and anti-inflammatory or steroidal detrimental effects when brought into contact with ocular agentina single formulation assistin restoring the injured eye tissue. In some instances, actives and/or excipients of the to its normal condition (i.e., non-inflamed and non-infected formulation may cause some discomfort or stinging in the state). 50 eye; however, those excipients are still considered ophthalmi The present invention utilizes physiologic levels of various cally-acceptable for the purposes of this application. In many serum electrolytes in an ophthalmic composition or formula instances, these irritating components are removed from the tion also containing an antimicrobial agent, and an anti-in formulations for comfort of the patient. For example, polyvi flammatory or steroidal agent for the treatment of various nyl alcohol (PVA) can be eliminated from the formulation ophthalmic injuries, diseases or disorders. Typically, the 55 ingredients. injury, disease or disorder results in an inflammatory response Antimicrobial compound includes those that effectively in and around the eye and/or causes leakage of the blood kill or mitigate the activity of a microbe.
Load more

Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Orange Book Cumulative Supplement 7 July 2006
    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • [email protected]
    SAFETY DATA SHEET Revision Date 13-Jul-2016 Version 1 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING Product identifier Product Name Pred Forte Other means of identification Product Code FP61 Synonyms Prednisolone Acetate Recommended use of the chemical and restrictions on use Recommended Use Corticosteroid This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient. Details of the supplier of the safety data sheet Manufacturer ALLERGAN 400 Interpace Parkway, Morris Corporate Center III Parsippany, NJ 07054, USA +1-800-272-5525 E-mail address [email protected] Emergency telephone number Emergency Telephone Call CHEMTREC Day or Night Within USA or Canada: 1-800-424-9300 Outside USA and Canada: +1-703-741-5970 (collect calls accepted) 2. HAZARDS IDENTIFICATION Classification OSHA Regulatory Status This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Reproductive toxicity Category 2 Effects on or via lactation Yes Label elements Emergency Overview Danger Hazard statements H362 - May cause harm to breast-fed
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Psorcon®(Diflorasone Diacetate Cream, USP)
    PSORCON- diflorasone diacetate cream Taro Pharmaceuticals U.S.A., Inc. ---------- psorcon® (diflorasone diacetate cream, USP) 0.05% Rx only For External Use Only - Not for Ophthalmic Use. DESCRIPTION PSORCON® (diflorasone diacetate cream USP), 0.05% contains the active compound diflorasone diacetate, a synthetic corticosteroid for topical dermatological use. Chemically, diflorasone diacetate is 6α, 9α-difluoro-11β,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17,21 diacetate, with the empirical formula C26H32F2O7, a molecular weight of 494.5, and the following structural formula: Each gram of PSORCON® (diflorasone diacetate cream USP), 0.05% contains 0.5 mg diflorasone diacetate in a cream base consisting of butylated hydroxytoluene, cetyl alcohol, citric acid, glyceryl stearate/PEG 100 stearate, isopropyl myristate, lanolin alcohol, mineral oil, monobasic sodium phosphate, polyoxyl 40 stearate, polysorbate 60, propylene glycol, purified water, sorbitan monostearate and vegetable oil. CLINICAL PHARMACOLOGY Like other topical corticosteroids, diflorasone diacetate has anti-inflammatory, anti-pruritic, and vasoconstrictive actions. The mechanism of the anti-inflammatory activity of the topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle and the integrity of the epidermal barrier. Occlusive dressings with hydrocortisone for up to 24 hours have not been demonstrated to increase penetration; however, occlusion of hydrocortisone for 96 hours markedly enhances penetration.
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • Prednisolone Also Binds to Transcortin • Other Synthetic GS Only Bind to Albumin
    PK/PD considerations for corticosteroids P L Toutain, National Veterinary School, Toulouse, France Wuhan October 2015 1 Anti-inflammatory drugs Corticosteroids NSAIDs 2 Glucocorticoids: main properties • Glucocorticosteroids (GCS) are broad and potent anti- inflammatory drugs. • They are extensively used to mitigate or suppress inflammation associated with a variety of conditions especially joint and respiratory system inflammation. • GCs are not curative: • GCs are only palliative symptomatic treatments and chronic use of GCs can be, in fine , detrimental • GCs possess many other pharmacological properties (not reviewed in this presentation) 3 The cortisol or hydrocortisone 4 Cortisol : An endogenous hormone and a surrogate endpoint of the duration of the GCS effects; it physiology should be understood to use properly GCS 5 Cortisol synthesis • All GCs used in therapeutics are synthetic derivatives of cortisol. • Cortisol (hydrocortisone) is synthesized in the adrenal cortex and it is the main corticosteroid hormone in most species. 6 Steroids synthesis by the adrenal gland Aldosterone Cortisol Androgens Epinephrine (adrenalin) 7 Cortisol ou Hydrocortisone structure – activity relationship Three structural properties are required for a GC activity (i.e. for cortisol to bind to GC receptor) 8 Cortisol (hydrocortisone) • Minimal information on cortisol physiology (secretion, distribution & elimination ) needs to be known to understand the clinical pharmacology of GCS 9 Plasma cortisol • Cortisol levels are very different in domestic species • Pattern of secretion – Circadian rhythm (h) – Pulsatilty (minute) 10 Plasma cortisol level Plasma concentration (ng/mL) 600 500 400 300 Series1 200 100 0 1 2 3 4 5 11 Plasma cortisol levels: circadian rhythm & pulsatility Toutain et al. Domestic.Anim.Endocrinol.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Pharmacy J-Code Billing/Topical Corticosteroid
    Pharmacy Services (800) 522-0114, option 4 October 14, 2019 RE: Pharmacy J-Code Billing, Topical Corticosteroid Update Dear SoonerCare Provider, The purpose of this fax is to provide reminders regarding pharmacy J-code (HCPCS) billing and updates regarding coverage of topical corticosteroids (TCS). Pharmacies cannot process HCPCS codes for reimbursement through SoonerCare. Pharmacies may submit claims for drug products with a National Drug Code (NDC) for reimbursement via a pharmacy claim. Claims for medications billed by a pharmacy on a CMS1500 for HCPCS codes or J-codes will not process through the SoonerCare claims systems. Effective November 12, 2019, the following changes will apply for the TCS medications category: . Temovate® (clobetasol propionate 0.05% ointment) will move from Tier-3 to Tier-1. Prior authorization will no longer be required. Diprosone® (betamethasone dipropionate 0.05% ointment) and Trianex® (triamcinolone acetonide 0.05% ointment) will move from Tier-1 to Tier-2. Apexicon® (diflorasone diacetate 0.05% cream and ointment) and Apexicon E® (diflorasone diacetate/emollient 0.05% cream) will move from Tier-2 to Tier-3. Current users will not be “grandfathered”. All members receiving these medications will require that a manual prior authorization be submitted by their prescriber. Specific prior authorization criteria and Tier charts for TCS medications can be downloaded from www.okhca.org/pa, then clicking “Topical”. If a member requires any of the above medications, prior authorization requests can be submitted for consideration to SoonerCare Pharmacy Services. Prior authorization request forms can be found online at www.okhca.org/rxforms (PHARM-04). Thank you for the services you provide to Oklahomans insured by SoonerCare! SoonerCare Pharmacy Services • Pharmacy Management Consultants • PO Box 26901; ORI W-4403• Oklahoma City, Oklahoma 73126-0901 • Phone: (800) 522-0114, option 4 • Fax: (800) 224-4014 .
    [Show full text]